Search
tavapadon
Indication:
- experimental treatment of Parkinson's disease (phase 3 trial)
Dosage:
- 5 mg to 15 mg PO QD
Adverse effects:
- decrease in supine blood pressure
- weight loss
- > 5%
- nausea (36 vs 11)*
- dyskinesia (25 vs4)
- dizziness (19 vs5)
- headache (17 vs 7)
- orthostatic hypotension (15 vs 3)
- visual hallucination (14 vs 3)*
* tavapadon vs placebo
Mechanism of action:
- selective partial D1/D5 dopamine receptor agonist
- agonist for dopamine D1 receptors & dopamine D5 receptors
General
neurologic agent
Database Correlations
PUBCHEM cid=86764100
References
- Wendling P
Positive Phase 3 Results for First-in-Class Parkinson's Med.
Medscape. October 10, 2024
https://www.medscape.com/viewarticle/positive-phase-3-results-first-class-parkinsons-med-2024a1000ijv